# QALSODY (tofersen) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tofersen

> The FDA approved QALSODY (tofersen), sponsored by BIOGEN INC. (BIIB), on April 25, 2023 for to treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is QALSODY (tofersen) FDA approved?

Yes. The FDA approved QALSODY (tofersen), sponsored by BIOGEN INC. (BIIB), on April 25, 2023 for to treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation. FDA novel drug approvals: "Qalsody | tofersen | 4/25/2023 | To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutationDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/tofersen)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/tofersen#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | QALSODY (tofersen) |
| Codes | BIIB067 |
| Sponsor | BIOGEN INC. (BIIB) https://sec-api.dev/companies/biib/catalysts |
| Indications | To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation, [Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation](https://sec-api.dev/indications/amyotrophic-lateral-sclerosis-associated-with-a-sod1-gene-mutation) |
| Modality | antisense |
| FDA designations | accelerated, orphan, priority review |

## Timeline

### April 25, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Qalsody | tofersen | 4/25/2023 | To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutationDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA215887 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20230425, review_priority PRIORITY; sponsor_name BIOGEN MA; product QALSODY (TOFERSEN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215887%22

### Aug to Nov 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04856982 (Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-07 (ESTIMATED); Lead Sponsor Biogen." https://clinicaltrials.gov/study/NCT04856982

### August 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04856982 (Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-07 (ESTIMATED); Lead Sponsor Biogen." https://clinicaltrials.gov/study/NCT04856982

Calendar months: [August 2027](https://sec-api.dev/fda-calendar/2027-08)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tofersen.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "QALSODY (tofersen) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tofersen

```bibtex
@misc{secapidev_pdufa_tofersen_20261116,
  title        = {QALSODY (tofersen) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tofersen}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tofersen_20261116","title":"QALSODY (tofersen) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tofersen","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
